Skip to search formSkip to main contentSkip to account menu

SB 200646A

Known as: SB-200646A, SKB-200646A 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The effects of combined administration of afobazole and 5-НТ2b/2c receptor antagonist SB-200646A on the content of monoamines and… 
2011
2011
Effects of separate and combined introduction of afobazole and SB-200646A (highly selective 5-HT2B/2C receptor antagonist) on the… 
2006
2006
This study examined the effect of the acute and chronic administration of the 5‐HT2B/2C receptor antagonist N‐(1‐methyl‐5‐indolyl… 
2005
2005
SB 200646A is the first selective 5-HT2C/5-HT2B receptor antagonist and has previously been observed to have anxiolytic-like… 
2000
2000
The NMDA receptor/nitric oxide (NO)/cyclic GMP pathway and its modulation by 5‐hydroxytryptamine (5‐HT) was studied in slices of… 
Highly Cited
1998
Highly Cited
1998
5-HT(2C) receptors are predominantly localised in the brain and their dysregulation may contribute to particular symptoms of…